Study of Antidiabetic Properties of Berberis asiatica and Withania somnifera in Streptozotocin-Nicotinamide-Induced Type II Diabetes Mellitus in Wistar Rats – PubMed Black Hawk Supplements

Abstract

Background and aim Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels. Although current antidiabetic drugs are highly effective, they are associated with various adverse drug reactions, including life-threatening hypoglycemia, skin rashes, and gastrointestinal intolerance, in addition to being costly. This animal-based experimental study aims to develop a herbal alternative or adjuvant to current antidiabetic drugs using Berberis asiatica (BA) and Withania somnifera (WS), which could potentially have fewer adverse drug reactions and reduce the required dose of existing antidiabetic medications. Material and methods Seventy-eight adult albino Wistar rats weighing between 150 and 250 g were used for the study. Diabetes mellitus (DM) was induced by intraperitoneal (i.p) injections of streptozotocin (STZ) (65 mg/kg) 15 minutes after nicotinamide (NIC) (110 mg/kg) administration. As the diabetes was confirmed (blood glucose level > 250 mg/dL), rats were divided into 13 different groups mentioned. The standard antidiabetic drugs (metformin [MET] and glimepiride [GLI]) and polyherbal combinations (PHC) (BA + WS) were administered orally, individually (WS and BA), and in combination (BA + WS). Blood samples were collected for biochemical analysis using the tail vein prick method. The study is based on a total of 13 groups, six rats in each group. Groups 1 and 2 (normal control [NC] and diabetic control [DC]) received distilled water at a dose of 10 mL/kg orally for 28 days. Groups 3-5 (BA 250, 500, and 1000) received dried ethanolic root extract of BA at a dose of 250, 500, and 1000 mg/kg orally, respectively, for 28 days. Groups 6-8 (WS 250, 500, and 1000) received dried ethanolic root extract of WS at a dose of 250, 500, and 1000 mg/kg orally, respectively, for 28 days. Groups 9-11 (PHC 250, 500, and 1000) received dried ethanolic root extract of BA + WS at a dose of 250, 500, and 1000 mg/kg orally, respectively, for 28 days. Groups 12 and 13 (MET and GLI) received standard drugs MET and GLI at a dose of 250 and 10 mg/kg orally, respectively, for 28 days. Results The dried ethanolic root extract of medicinal herbal plants BA and WS and their combination exhibited significant antidiabetic efficacy. PHC has been shown to have a superior antidiabetic effect than individuals. PHC 500 and 1000 showed blood glucose levels similar to those of the GLI group (P < 0.05). Additionally, PHC 1000 showed blood glucose levels similar to those of the MET group (P < 0.05). Conclusion Our results indicate that both BA and WS possess hypoglycemic activity, and their combination also has a synergistic antidiabetic effect compared to the individual extract. These findings are promising in developing new safe and cost-effective herbal combinations as alternatives or additives to currently used synthetic antidiabetic drugs.

Keywords: animal study; combination effect; diabetes type 2; ethanolic plant extract; herbal drugs.

Conflict of interest statement

Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Animal subjects: The approval was taken from the Institutional Ethics Committee of Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, India (IEC Approval no. 385/2020-2021), and the Institutional Animal Ethics Committee of Krishna Vishwa Vidyapeeth (Deemed to be University) Reg. No. 255/PO/REBi/S/2000/CPCSEA (IAEC Approval no. IAEC/KIMS/2021/16). The rats were injected, orally fed, and sacrificed according to guidelines by the Committee for Purpose of Control and Supervision of Experiments on Animals (CPCSEA) and the Indian National Science Academy Guidelines (INSA) in the Central Animal House, KIMSDU. Issued protocol number 385/2020-2021. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Similar articles

• Effect of Withania somnifera on insulin sensitivity in non-insulin-dependent diabetes mellitus rats.

  Anwer T, Sharma M, Pillai KK, Iqbal M. Anwer T, et al. Basic Clin Pharmacol Toxicol. 2008 Jun;102(6):498-503. doi: 10.1111/j.1742-7843.2008.00223.x. Epub 2008 Mar 16. Basic Clin Pharmacol Toxicol. 2008. PMID: 18346053

• Anti-diabetic property of ethanolic extract of Andrographis paniculata in streptozotocin-diabetic rats.

  Zhang XF, Tan BK. Zhang XF, et al. Acta Pharmacol Sin. 2000 Dec;21(12):1157-64. Acta Pharmacol Sin. 2000. PMID: 11603293

• Antidiabetic and hypolipidemic activities of hydroethanolic root extract of Uvaria chamae in streptozotocin induced diabetic albino rats.

  Emordi JE, Agbaje EO, Oreagba IA, Iribhogbe OI. Emordi JE, et al. BMC Complement Altern Med. 2016 Nov 15;16(1):468. doi: 10.1186/s12906-016-1450-0. BMC Complement Altern Med. 2016. PMID: 27846886 Free PMC article.

• The Anti-Diabetic Effect of Some Plant Extracts Against Streptozotocin – Induced Diabetes Type 2 in Male Albino Rats.

  Gomaa HF, Abdelmalek IB, Abdel-Wahhab KG. Gomaa HF, et al. Endocr Metab Immune Disord Drug Targets. 2021;21(8):1431-1440. doi: 10.2174/1871530320666201016145502. Endocr Metab Immune Disord Drug Targets. 2021. PMID: 33069202

• Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

  Plosker GL, Figgitt DP. Plosker GL, et al. Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.